CONNEQT Health to Host Investor Webinar on Q4 Results Featuring CEO Craig Cooper and Leadership Team

CONNEQT Health’s Vascular Health Technology and Market Positioning

Operating in the medical technology industry, CONNEQT Health Limited specialises in vascular health solutions and cardiovascular disease management. The company’s mission is to enhance longevity through innovative vascular health technologies, positioning it prominently within the healthcare technology and medical devices market. This focus addresses a substantial market opportunity amid the global prevalence of cardiovascular disease and hypertension, particularly within aging populations in developed countries.

Its product range includes a comprehensive array of medical and home health devices complemented by digital solutions targeting hypertension, cardiovascular disease, and other vascular disorders. These products are underpinned by CONNEQT Health’s proprietary SphygmoCor4 vascular biomarker technology, which the company identifies as market-leading. The SphygmoCor4 platform serves as a critical competitive advantage and intellectual property asset, enabling integrated solutions across clinical and home health environments. This technology foundation supports the company’s strategy to expand across multiple vascular health market segments.

Investor Webinar Schedule and Leadership Engagement

CONNEQT Health will hold its investor webinar on Wednesday, 22 July 2026 at 9:00am Australian Eastern Standard Time, corresponding to 4:00pm Pacific Daylight Time on Tuesday, 21 July 2026 for international attendees. The webinar follows the release of the company’s quarterly activities report, providing an in-depth discussion on Q4 results and operational matters. This timing aligns with best practices for transparent investor communication, enabling shareholders to gain comprehensive insights into recent performance.

CEO Craig Cooper will host the webinar, joined by Executive Chairman Niall Cairns and Chief Strategy Officer Catherine Liao. This multi-executive participation offers investors access to leadership across strategic, governance, and planning functions. The involvement of several senior executives underscores the company’s intent to deliver a substantive dialogue, potentially highlighting significant developments or strategic initiatives warranting broad leadership input and investor engagement.

Investor Registration and Participation Details

Investors interested in attending can register through a Zoom webinar link provided by CONNEQT Health. Registrants will receive confirmation emails containing the necessary technical details to join the session. This digital format facilitates wide investor participation regardless of geographic location, removing barriers to access and reflecting modern investor relations standards.

Participants are encouraged to submit questions in advance via [email protected]. This allows the leadership team to prepare thorough responses to investor inquiries. By offering both live participation and pre-submitted question options, CONNEQT Health aims to maximize investor engagement and address diverse interests related to the company’s Q4 performance and future strategy.

Focus Areas for Q4 Results and Operational Discussion

The webinar will concentrate on CONNEQT Health’s Q4 financial results and operational activities, complementing the company’s quarterly activities report. This dual approach ensures investors receive both formal data disclosures and executive commentary, enhancing decision-making through comprehensive insights.

Discussion topics are expected to cover financial performance, operational metrics, and cash flow during the final quarter of the fiscal year. Updates on product commercialization, market expansion strategies for vascular health solutions, and progress on key business initiatives will likely be addressed. The participation of the Chief Strategy Officer indicates that strategic market positioning and forward-looking operational plans will be integral to the dialogue alongside retrospective performance analysis.

Leadership Roles and Governance in Investor Communications

CEO Craig Cooper’s involvement highlights his direct role in investor relations and operational oversight at CONNEQT Health. His presence demonstrates the company’s commitment to transparent communication regarding business strategy and performance.

Executive Chairman Niall Cairns will contribute governance insights, reflecting his role in board-level strategic guidance and operational oversight. Chief Strategy Officer Catherine Liao’s participation emphasizes the importance of strategic planning and market opportunity discussions. This comprehensive leadership engagement illustrates the company’s dedication to addressing both historical results and future strategic directions from multiple executive perspectives.

Commitment to Investor Transparency and Market Best Practices

By scheduling a structured investor webinar aligned with quarterly disclosures, CONNEQT Health adheres to ASX-listed company best practices in investor relations. The provision of advance registration, technical support, and pre-submitted questions facilitates broad investor access and engagement. This approach promotes equal access to material information, ensuring shareholders worldwide can participate fully in discussions of company performance and strategy.

The announcement’s formal approval by the Board of Directors confirms appropriate governance oversight of investor communications. The involvement of the Company Secretary in releasing the statement further underscores CONNEQT Health’s adherence to ASX disclosure protocols and corporate governance standards.

Medical Device Industry Context and Vascular Health Market Drivers

CONNEQT Health operates within the medical devices sector, focusing on vascular health and cardiovascular disease management. This segment requires rigorous clinical validation, regulatory approvals, and evidence-based demonstration of clinical benefits. The company’s emphasis on hypertension and cardiovascular disease aligns with growing clinical demand driven by aging populations and expanding chronic disease management needs in developed markets.

Its integration of medical devices with digital health solutions reflects industry trends toward combining hardware and software for enhanced patient care. Home health devices and digital platforms are expanding segments within cardiovascular management, fueled by demand for remote monitoring, patient engagement, and integrated data analytics. CONNEQT Health’s positioning across clinical and home health settings enables it to capture opportunities throughout the vascular health care continuum.

Competitive Edge and Intellectual Property via SphygmoCor4 Technology

CONNEQT Health’s product suite is anchored by its proprietary SphygmoCor4 vascular biomarker technology, recognized as market-leading. This technology constitutes a vital competitive asset and intellectual property foundation, enabling precise measurement and analysis of vascular function for diagnostic and monitoring applications in cardiovascular and hypertension care. The established clinical validation and market recognition of SphygmoCor4 strengthen the company’s competitive positioning.

Leveraging SphygmoCor4 across multiple product lines—including medical devices, home health products, and digital solutions—reflects a platform strategy that supports efficient development, cross-selling, and integrated vascular health management solutions. This intellectual property is a key contributor to CONNEQT Health’s market differentiation within the vascular health and medical device sectors.